2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
By: Ross Blau
Westlaw Journal
Ross Blau co-authored, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" with Jonathan Harris and Drew Hillier which was published by Westlaw Journal Medical Devices, Westlaw Journal Products Liability, Westlaw Journal Health Law, Westlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
What’s Up? Enforcement Updates From the Middle East and Africa
Podcast
Antitrust
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Lexology In-Depth: Intellectual Property and Antitrust (2026)
Byline Articles
Intellectual Property
Tracking The Rare 'Quick Look' Win In FTC's Zillow-Redfin Suit
Byline Articles
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
What Top Law Firms Say New Lawyers Need in the AI Era
Media Mentions
What’s the Role of Communications Strategy in M&A? How Public Affairs Impacts Antitrust
Podcast
Antitrust
